Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study

被引：21
|
作者：
Wessels, Alette M. [1 ]
Bies, Robert R. [1 ,2 ]
Pollock, Bruce G. [2 ,3 ,4 ]
Schneider, Lon S. [5 ]
Lieberman, Jeffrey A. [6 ,9 ,10 ,11 ,12 ,13 ,14 ]
Stroup, Scott [6 ]
Li, Claire H. [1 ]
Coley, Kim [7 ]
Kirshner, Margaret M. [4 ]
Marder, Stephen R. [8 ,15 ,16 ,17 ,18 ,19 ,20 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN USA
[2] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada
[3] Univ Toronto, Baycrest Hosp, Rotman Res Inst, Toronto, ON, Canada
[4] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[5] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[6] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA
[7] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA
[8] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA
[9] GlaxoSmithKline, London, England
[10] Intracellular Therapies, New York, NY 10032 USA
[11] Eli Lilly & Co, Indianapolis, IN USA
[12] Pierre Fabre, Castres, France
[13] Psychogenics, Tarrytown, NY USA
[14] Wyeth, Madison, NJ USA
[15] Advisory Board Wyeth, Madison, NJ USA
[16] Otsuka, Tokyo, Japan
[17] Sanofi Aventis, Bombay, Maharashtra, India
[18] Lundbeck, Copenhagen, Denmark
[19] Pfizer, New York, NY USA
[20] Schering Plough Corp, Kenilworth, NJ 07033 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 11期
基金：
加拿大健康研究院;
关键词：
ziprasidone; population pharmacokinetics; schizophrenia; CLINICAL ANTIPSYCHOTIC TRIALS; PROJECT; IMPACT; DRUG; RACE;
D O I：
10.1177/0091270010387604
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：1587 / 1591
页数：5
相关论文
共 50 条
  • [41] Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia
    Wang, Wenyan
    Wang, Xiaofeng
    Dong, Ying
    Walling, David P.
    Liu, Pinglan
    Liu, Wanhui
    Shi, Yanan
    Sun, Kaoxiang
    NEUROLOGY AND THERAPY, 2024, 13 (02) : 355 - 372
  • [42] Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia
    Wenyan Wang
    Xiaofeng Wang
    Ying Dong
    David P. Walling
    Pinglan Liu
    Wanhui Liu
    Yanan Shi
    Kaoxiang Sun
    Neurology and Therapy, 2024, 13 : 355 - 372
  • [43] Substance use and schizophrenia: Adverse correlates in the CATIE study sample
    Kerfoot, Karin E.
    Rosenheck, Robert A.
    Petrakis, Ismene L.
    Swartz, Marvin S.
    Keefe, Richard S. E.
    McEvoy, Joseph P.
    Stroup, T. Scott
    SCHIZOPHRENIA RESEARCH, 2011, 132 (2-3) : 177 - 182
  • [44] Genomewide association for schizophrenia in the CATIE study: results of stage 1
    P F Sullivan
    D Lin
    J-Y Tzeng
    E van den Oord
    D Perkins
    T S Stroup
    M Wagner
    S Lee
    F A Wright
    F Zou
    W Liu
    A M Downing
    J Lieberman
    S L Close
    Molecular Psychiatry, 2008, 13 : 570 - 584
  • [45] Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study
    Stroup, T. Scott
    Lieberman, Jeffrey A.
    McEvoy, Joseph P.
    Swartz, Marvin S.
    Davis, Sonia M.
    Capuano, George A.
    Rosenheck, Robert A.
    Keefe, Richard S. E.
    Miller, Alexander L.
    Belz, Irving
    Hsiao, John K.
    AMERICAN JOURNAL OF PSYCHIATRY, 2007, 164 (03): : 415 - 427
  • [46] A Candidate Gene Study of Tardive Dyskinesia in the CATIE Schizophrenia Trial
    Tsai, Huei-Ting
    Caroff, Stanley N.
    Miller, Del D.
    McEvoy, Joseph
    Lieberman, Jeffrey A.
    North, Kari E.
    Stroup, T. Scott
    Sullivan, Patrick F.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2010, 153B (01) : 336 - 340
  • [47] Effect of ziprasidone on QTc interval in Chinese patients with schizophrenia
    YANG Xiaobo
    YUAN Zuyi
    CAO Hongmei
    MA Xiancang
    Journal of Medical Colleges of PLA, 2013, 28 (06) : 368 - 372
  • [48] Genomewide association for schizophrenia in the CATIE study: results of stage 1
    Sullivan, P. F.
    Lin, D.
    Tzeng, J-Y
    van den Oord, E.
    Perkins, D.
    Stroup, T. S.
    Wagner, M.
    Lee, S.
    Wright, F. A.
    Zou, F.
    Liu, W.
    Downing, A. M.
    Lieberman, J.
    Close, S. L.
    MOLECULAR PSYCHIATRY, 2008, 13 (06) : 570 - 584
  • [49] Predictive value of early improvement with ziprasidone in patients with schizophrenia
    Kane, John M.
    Vanderburg, Douglas
    Batzar, Evan
    Loebel, Antony D.
    Walker, Jill Kerrick
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 165S - 165S
  • [50] Use of ziprasidone in patients with schizophrenia in four European countries
    Montes, J-M
    EUROPEAN PSYCHIATRY, 2011, 26 : 29 - 37
12345